Neurodegenerative Diseases: Recent Advances and Future Perspectives—Volume II

Dear Colleagues,

This Special Issue is the second volume of “Neurodegenerative Diseases: Recent Advances and Future Perspectives”.

Neurodegenerative disorders impact a significant portion of the global population, and their prevalence is increasing in tandem with rising life expectancies. Conditions such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, ataxias, and glaucoma are characterized by progressive neuronal deterioration and the disruption of neural connectivity, leading to impairment in mobility, coordination, strength, sensation, cognition, and vision.

These complex neurodegenerative ailments share underlying molecular and cellular features, including oxidative stress, mitochondrial dysfunction, protein misfolding, excitotoxicity, and inflammation. Despite ongoing research, definitive therapeutic interventions to cure or halt disease progression remain difficult to achieve. Consequently, investigations into early detection, disease onset, and innovative therapeutic strategies are paramount.

Research avenues encompass a wide range of methodologies, including animal models that reproduce pathological features, patient-derived pluripotent stem cell lines, organoid generation, and biomarker studies that assess retinal and ophthalmologic changes, protein profiles in various body fluids, and functional and structural assessments. These approaches are employed in both affected individuals and those at high genetic risk, contributing to a comprehensive understanding of disease mechanisms.

This Special Issue, under the direction of Dr. López-Cuenca and Dr. De Hoz, will highlight recent advances in the fields of basic, translational, and clinical research in neurodegenerative diseases. It aims at expanding knowledge on the pathophysiological mechanisms and therapeutic pathways for these disabling diseases.

Dr. Inés López-Cuenca
Dr. Rosa De Hoz
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• neurodegeneration
• neuroprotection
• dementia
• Parkinson’s disease

• Neurodegenerative Diseases: Recent Advances and Future Perspectives in Biomedicines (13 articles)